Arcturus Therapeutics Holdings Inc Revenue Growth Rates (ARCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arcturus Therapeutics Holdings Inc   (NASDAQ: ARCT)
 

ARCT's Revenue Growth by Quarter and Year

Arcturus Therapeutics Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ARCT/growth
https://api.csimarket.com/api/v1/companies/ARCT/fundamentals
https://api.csimarket.com/api/v1/companies/ARCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ARCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.30
2nd Quarter June 2.96
1st Quarter March 2.06
FY 23.32

ARCTs Annual Revenue
Arcturus Therapeutics Holdings Inc 's Revenue in the fiscal year 2025 $ 82.03 millions
Arcturus Therapeutics Holdings Inc 's Revenue in the fiscal year 2024 $ 152.31 millions
Arcturus Therapeutics Holdings Inc 's Revenue in the fiscal year 2023 $ 166.80 millions
Arcturus Therapeutics Holdings Inc 's Revenue in the fiscal year 2022 $ 206.00 millions
Arcturus Therapeutics Holdings Inc 's Revenue in the fiscal year 2021 $ 12.36 millions




ARCT Revenue third quarter 2026 Y/Y Growth Comment
Arcturus Therapeutics Holdings Inc reported Revenue growth of 6.69% year on year in the third quarter 2026, to $ 18.30 millions, this is lower than Arcturus Therapeutics Holdings Inc 's recent average Revenue surge of 190.05%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 191 other companies have achieved higher Revenue growth. While Arcturus Therapeutics Holdings Inc ' s Revenue increase of 6.69% ranks overall at the positon no. 3902 in the third quarter 2026.


ARCT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.69 %
2nd Quarter June -89.54 %
1st Quarter March -92.99 %
FY   -

Financial Statements
Arcturus Therapeutics Holdings Inc 's third quarter 2026 Revenue $ 18.30 millions ARCT's Income Statement
Arcturus Therapeutics Holdings Inc 's third quarter 2025 Revenue $ 17.15 millions Quarterly ARCT's Income Statement


ARCT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 518.14 %
2nd Quarter June 43.69 %
1st Quarter March -71.39 %
FY (Year on Year)   -


Back to ARCT Growth rate Comparisons >> Back to ARCT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #192
Healthcare Sector #560
Overall #3902

Revenue Y/Y Growth Statistics
High Average Low
2666.53 % 190.05 % -92.99 %
(Mar 31 2023)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #192
Healthcare Sector #560
Overall #3902
Revenue Y/Y Growth Statistics
High Average Low
2666.53 % 190.05 % -92.99 %
(Mar 31 2023)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Arcturus Therapeutics Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1098.99 % 47.88 % -86.9 %
(Dec 31 2022)  


ARCT's III. Quarter Q/Q Revenue Comment
Arcturus Therapeutics Holdings Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 518.14%, to $ 18.30 millions, from $2.96 millions in the second quarter.
ARCT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Arcturus Therapeutics Holdings Inc 's Revenue growth quarter on quarter, overall rank is 277.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #73
Overall #277
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #73
Overall #277
Revenue Q/Q Growth Statistics
High Average Low
1098.99 % 47.88 % -86.9 %
(Dec 31 2022)  


ARCT's III. Quarter Q/Q Revenue Comment
Arcturus Therapeutics Holdings Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 518.14%, to $ 18.30 millions, from $2.96 millions in the second quarter.
ARCT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Arcturus Therapeutics Holdings Inc 's Revenue growth quarter on quarter, overall rank is 277.


Arcturus Therapeutics Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 29.37
Y / Y Revenue Growth (TTM) -75.95 %
Year on Year Revenue Growth Overall Ranking # 3486
Seqeuential Revenue Change (TTM) -46.32 %
Seq. Revenue Growth (TTM) Overall Ranking # 3335


Cumulative Revenue growth Comment
Arcturus Therapeutics Holdings Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -75.95% year on year, at Jun 30 2026 compare to the -61.92% decrease at Mar 31 2026. If the Arcturus Therapeutics Holdings Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $29 millions.

In the Healthcare sector 467 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 845 to 3486.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 468
Overall # 3486

Revenue TTM Y/Y Growth Statistics
High Average Low
1715.97 %
 161.96 %
-75.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 146
Sector # 446
S&P 500 # 3335
Cumulative Revenue growth Comment
Arcturus Therapeutics Holdings Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -75.95% year on year, at Jun 30 2026 compare to the -61.92% decrease at Mar 31 2026. If the Arcturus Therapeutics Holdings Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $29 millions.

In the Healthcare sector 467 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 845 to 3486.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 468
Overall # 3486

Revenue TTM Y/Y Growth Statistics
High Average Low
1715.97 %
161.96 %
-75.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 146
Sector # 446
S&P 500 # 3335




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions
Warby Parker Inc 10.77%$ 10.767 millions
Cerus Corporation10.69%$ 10.690 millions
Biogen Inc 10.63%$ 10.628 millions
Chemed Corporation10.57%$ 10.568 millions
Edwards Lifesciences Corporation10.47%$ 10.471 millions
Biodesix Inc 10.44%$ 10.442 millions
Medline Inc 10.41%$ 10.415 millions
Jazz Pharmaceuticals Plc10.38%$ 10.380 millions
Abbvie Inc 10.32%$ 10.319 millions
Livanova Plc10.17%$ 10.170 millions
Kura Oncology Inc 10.07%$ 10.067 millions
Amneal Pharmaceuticals Inc 10.04%$ 10.040 millions
Quest Diagnostics Inc9.98%$ 9.979 millions
Idexx Laboratories Inc9.95%$ 9.950 millions
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions
Haemonetics Corporation9.49%$ 9.492 millions


About Arcturus Therapeutics Holdings Inc Revenue Growth Rates (ARCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.